Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II

Journal of Cardiac Failure

Volumn 5, Issue 2, 1999, Pages 146-154

  Pitt, Bertram ^a   Poole Wilson, Philip ^b   Segal, Robert ^c   Martinez, Felipe A ^d   Dickstein, Kenneth ^e   Camm, A John ^f   Konstam, Marvin A ^g   Riegger, Günter ^h   Klinger, George H ^c   Neaton, James ⁱ   Sharma, Divakar ^c   Thiyagarajan, Balasamy ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^g TUFTS MEDICAL CENTER   (United States)

^h UNIVERSITY OF REGENSBURG   (Germany)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

Author keywords

ACE inhibitor; Angiotensin II antagonist; Morbidity; Survival

Indexed keywords

CAPTOPRIL; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SUDDEN DEATH; SURVIVAL RATE;

EID: 13044312091     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(99)90037-4     Document Type: Article

References (18)

1. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273: 1450-6
2. Bart BA, Gattis WA, Diem SJ, O'Connor CM: Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997;79:1118-20
3. Uretsky BF, Sheahan RG: Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 1997;30:1589-97
4. Pahor M, Gambissi G, Carboni P: Antiarrhythmic effects of ACE inhibitors: a matter of faith or reality. Cardiovasc Res 1994;28:173-82
5. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI on behalf of the ELITE Study Investigators: Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52
6. Brooksby P, Cowley A, Segal R, Robinson P, Klinger G, Pitt B: Effects of losartan and captopril on QT dispersion in elderly patients with heart failure in the ELITE study; an initial assessment. Eur Heart J 1998;19:133 (abstr, suppl)
7. Rump LC, Oberhauser V, Schwertfeger E, Schollmeyer P: Experimental evidence to support ELITE. Lancet 1998; 351:644-5
8. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP for the SWORD Investigators: Effect of d-sotalal on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12
9. Packer M, Lee WH, Yushak M, Medina N: Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1987;315:847-53
10. Pitt B: Effects of angiotensin II antagonists in comparison to ACE inhibitors in patients with heart failure due to systolic left ventricular dysfunction. Heart Fail Rev 1999;3:221-32
11. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, Yusuf S for the SOLVD Investigators: Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-7
12. Thomas G, Ferrier G, Howlett S: Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharm Exp Ther 1996;278:1090-7
13. Lynch Jr JJ, Stump GL, Wallace AA, Painter CA, Thomas JM, Kusma SE, Gould RJ, Grossman W: EXP3174, the All antagonist human metabolite of losartan, but not losartan nor the ACE-inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. J Am Coll Cardiol (in press)
14. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD: QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-9
15. Elming H, Holm E, Jun L, Torp-Pederson C, Kober L, Kircshoff M, Malik M, Camm J: The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J 1998;19:1391-400
16. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM on behalf of the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327: 699-77
17. Cohn JN: The management of chronic heart failure. N Engl J Med 1996;335:490-8
18. Hamroff G, Blaufarb I, Mancini D, Katz S, Bijou R, Jondeau G, Olivari M-T, Thomas S, LeJemtel T: Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despite full angiotensin-converting enzyme inhibition. J Am Coll Cardiol 1998;31:188A (abstr)